Prophylactic surgery rates among men with breast cancer nearly double
the ONA take:
The rates of contralateral prophylactic mastectomy (CPM) among men with breast nearly doubled between 2004 and 2011, which mirrors a trend seen in women with breast cancer, according to a report from American Cancer Society and Dana Farber Cancer Institute researchers.
In women, particularly younger women, use of CPM has increased over the past two decades despite a lack of evidence for survival benefit, associated costs, and possible complications. Breast cancer in men accounts for approximately 1% of all cases in the United States.
The researchers pulled nationwide data from the North American Association of Central Cancer Registries on 6,332 men who underwent surgery for breast cancer limited to one breast between 2004 and 2011.
Rate of CMP among men increased from 3.0% in 2004 to 5.6% in 2011. The sociodemographic factors linked to more surgery in men were similar to those for women who underwent CPM: being white, younger age, and having private insurance.
However, the study did not have data on other factors linked to women who choose to undergo CPM, such as genetic testing, family history, magnetic resonance imaging, or fear of breast cancer occurring in the other breast.
The rates of contralateral prophylactic mastectomy (CPM) among men with breast nearly doubled between 2004 and 2011.
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Study Affirms Activity of Ibrutinib in Patients With R/R CLL With 17p Deletion
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Longer Maintenance Therapy Duration May Improve Survival in Myeloma
- HRQoL Better Maintained With Pembrolizumab in Ipilimumab-refractory Melanoma
- Economic Evaluation of Obinutuzumab in Combination With Chlorambucil in First-line Treatment of Patients With Chronic Lymphocytic Leukemia in Spain
- MRD Assessment Improves PFS Prediction in Patients With CLL
- Cancer Patients Have Unrealistic Hopes When Entering Clinical Trials
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|